Most Covid-19 Treatments Found to Be Free of Serious Side Effects in Analysis of Us Studies

NUMEROUS TREATMENT OPTIONS FOR COVID-19 have Been Approved by the US Food and Drug Administration Over the Last Four Years, Including Antiviral Drugs and Monoclonal Antibodies That Suppress An Excessive Immune Response. NOW, Research from the Keck School of Medicine of Usc has Found That Covid-19 Therapies Cause FEIOUS SIDE Effects, Based on An Evaluation of the Full Spectrum of Evidence Available from Us Us Biomedical Science.

In the Significant Association with Serious Adverse Events was Found for Oral Antivirals Such as Paxlovid. Evusheld and other monoclonal antibodies that bind to the coronavirus’s Spike Protein, Previously Administred Intravenly in Hospital But in the longer authorized by the fda due to the their of effectiveness against covid-19 variants, were not associated with serous adverse events. ACTEM, AN IV MONOCLONAL ANTIBODY THAT WORKS SOMEWHAT DIFFERENTLY AND IS ALSO KNOWN BY THE GENERIC NAME TOCILIMAB, WAS ASSOCIATED WITH INFECTION AND LOW WHITE BLOOD CENTRS IN SOME STUDIES.

Transfusions of convalescent plasma-the Blood Product Taken from recovered Covid-19 Patients-Wer Linked with Higher Risk of Internal Bleeding, Infection and Blood Clots. The Serious Adverse Events Identified Align with Current Product Labeling.

Most People Who Contract Covid-19 will be able to recover from the infection Without a prescription. However, Physicians May Prescription Treatments for Patients With Risk Factors Such As Advanced Age, Obesity, Cardiovascular Issues, Diabetes Or A Committed Immune System. The Keck School of Medicine Findings Should eat Good News to these People.

“The Main Message is, if you doctor puts you on paxlovid, you don’t have to work to work serious side effects,” Said Susanne Hempel, Ph.D., Professor of Clinical Population and Public Health Sciences and Director of the Southern California Evidence Review Center Keck School of Medicine, Who Overseaw the Work. “There are no Serious Adversy Events for Any of the Oral Medications That You’re Taking at Home For Covid-19.”

The Review, published in Open Forum Infectious DiseasesIncorporated 54 STUDIES SPANNING INPATIENT AND OUTPATIENT TREATMENT, Clinical Trials and Observational Research. Only Investigations Comparing Covid-19 Therapy with Standard Care, Placebo or on Treatment Were Examined, So That Effects of the Disease Itself Could Reasonably Be Excluded. Hempel and Her Colleagues Reated Beyond Peer-RevieWed Research to Include Date Submitted to the FDA and to the National Library of Medicine’s Clinicaltrials.gov Site.

Rigorous science to informu public policy

Governmentary Agencies Regularly Call Upon the ERC –one of Nine Evidence-Based Practice Centers Nationwide-to Provide Detailed Analyses That Inform Public Policy.

The Current Study was driven by the Need to Develop to Countermeasure Injury Compensation Table, Which is Used to Determine WHETHER PATIES AND FAMILIES WHATE REPORT ADVERSE Events Are ELIGIBLE FOR PUBLIC BENEFITS. “Given the Unique Nature of the Pandemic and the Rapid Production of Treatments for Covid-19, The Findings Are Very Reassuring,” Said Co-Author and Infectious Disease Expert Jeffrey Klausner, MD, MPH, Professor of Clinical Population and Public Health Sciences in the Keck School of Medicine.

“With a Seven Public Health Emergency Like Covid-19, It is critical that they exist the government compensation program for treatment-relanted injuries that is based on the best scientific evidence. Frequency of Serious Side Effects. “

FOCUSING ON THE MOST SEVERE OUTCOMES

The Study Concentrated Only On Serious Side Effects, AS Defined by A Standard Scale Developed by the National Institutes of Health. On the Five-Point Scale, the Rating of Three or Above Indicates Severe Conditions That Require Hospitalization; The Highest Grade of Five signifies the fatal event.

“Manufacturers Must Submit Very Detailed Records to the FDA for Emergency Authorization, So Every Advey Event Should Have Been Reported,” Said First Author Margaret Maglione, MPP, A Project Leader at the ERC. “We Did Not Identify Any Serious Adverse Events That Were Not Already Description on the Product Packaging.”

About This Study

Other co-authors of the Study Are Patricia Wirnkar, Ivan Fallarme, Rozhin Lak, Kimny Sysawang, Ning Fu, Sachi Yagyu, Anesis Motala and Danica Tolentino, All of USC.